Karsten Witt
President bei KW Biotech Consulting LLC
Profil
Karsten Witt currently works at KW Biotech Consulting LLC, as President from 2013.
Dr. Witt also formerly worked at Topotarget A, as Director in 2011, OSI Pharmaceuticals, Inc., as Senior Vice President-Pharmaceutical Operations, Array BioPharma, Inc., as Vice President-Clinical Sciences from 2011 to 2013, and Black Diamond Therapeutics, Inc., as Chief Medical Officer & VP-Clinical Development from 2021 to 2022.
Dr. Witt received his doctorate degree in 1985 from the University of Copenhagen.
Aktive Positionen von Karsten Witt
| Unternehmen | Position | Beginn |
|---|---|---|
| KW Biotech Consulting LLC | President | 01.02.2013 |
Ehemalige bekannte Positionen von Karsten Witt
| Unternehmen | Position | Ende |
|---|---|---|
| BLACK DIAMOND THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 08.09.2020 |
| ARRAY TECHNOLOGIES, INC. | Chief Tech/Sci/R&D Officer | 01.01.2013 |
| OSI PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
| TOPOTARGET A/S | Director/Board Member | - |
Ausbildung von Karsten Witt
| University of Copenhagen | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| BLACK DIAMOND THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 4 |
|---|---|
OSI Pharmaceuticals, Inc.
 OSI Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OSI Pharmaceuticals, Inc. manufactured and develope dpharmaceutical drugs. The company was founded in 1983 and was headquartered in Farmingdale, NY. | Health Technology |
Array BioPharma, Inc.
 Array BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Array BioPharma, Inc. is a biopharmaceutical company. Its focus is on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer and other high-burden diseases. The company's products are BRAFTOVI and MEKTOVI. Its portfolio includes Binimetinib, Selumetinib, Encorafenib, Filanesib, Ipatasertib, Varltinib, Danoprevir, ARRY-797, Larotrectinib, Tucatinib, ARRY-382, Motolimod, Prexasertib, GDC-0575, LOXO-292, LOXO-195, and AK-1830. The company was founded by Kevin Koch, Anthony D. Piscopio, K. C. Nicolaou, and David L. Snitman in 1998 and is headquartered in Boulder, CO. | Health Technology |
Topotarget A/S
 Topotarget A/S Pharmaceuticals: MajorHealth Technology Topotarget A/S is a biotechnology company that is engaged in the development and commercialization of novel drugs for the treatment of cancer. Its product belinostat is a novel histone deacetylase inhibitor which is used for cancer patients. The company was founded by Peter Buhl Jensen and Maxwell Sehested in 2000 and is headquartered in Copenhagen, Denmark. | Health Technology |
| KW Biotech Consulting LLC |
